New and future immunomodulatory therapy in type 1 diabetes
Authors:
- Frank Waldron-LynchFWFrank Waldron-Lynch
- Kevan C. HeroldKHKevan C. Herold
- 1 March 2012
- journal article
- review article
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 18 (3) , 173-181
Abstract
No abstract availableKeywords
This publication has 77 references indexed in Scilit:
- Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trialThe Lancet, 2011
- Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trialThe Lancet, 2011
- Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trialThe Lancet, 2011
- T‐cell autoantigens in the non‐obese diabetic mouse model of autoimmune diabetesImmunology, 2010
- IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cellsJournal of Experimental Medicine, 2010
- Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 yearsClinical Immunology, 2009
- GAD Treatment and Insulin Secretion in Recent-Onset Type 1 DiabetesNew England Journal of Medicine, 2008
- Innate immunity and intestinal microbiota in the development of Type 1 diabetesNature, 2008
- Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-ANature, 2007
- Comparative therapeutic effects of orally administered 1,25-dihydroxyvitamin D3 and 1alpha-hydroxyvitamin D3 on type-1 diabetes in non-obese diabetic mice fed a normal-calcaemic dietClinical and Experimental Immunology, 2007